Cargando…

A rare case report of recurrent atypical meningioma with multiple metastases treated with anti-PD-1 and anti-VEGF therapy

BACKGROUND: Meningioma is the most common type of primary intracranial tumor with 0.1–1% of all primary meningiomas have been reported to develop into metastases. However, there is no proven therapeutic strategy for multiple metastases of meningiomas. CASE PRESENTATION: A 60-year-old female accepted...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Jia-Li, Liu, Jing, Fang, Ming, Luo, Chen, Gu, Zhen-Bang, Huang, Long
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9588214/
https://www.ncbi.nlm.nih.gov/pubmed/36273133
http://dx.doi.org/10.1186/s12883-022-02919-4
_version_ 1784814078777098240
author Zhao, Jia-Li
Liu, Jing
Fang, Ming
Luo, Chen
Gu, Zhen-Bang
Huang, Long
author_facet Zhao, Jia-Li
Liu, Jing
Fang, Ming
Luo, Chen
Gu, Zhen-Bang
Huang, Long
author_sort Zhao, Jia-Li
collection PubMed
description BACKGROUND: Meningioma is the most common type of primary intracranial tumor with 0.1–1% of all primary meningiomas have been reported to develop into metastases. However, there is no proven therapeutic strategy for multiple metastases of meningiomas. CASE PRESENTATION: A 60-year-old female accepted total tumor resection of a right frontal lobe meningioma in September 2018, In October 2021, the patient was admitted to hospital because of cough and shortness of breath and diagnosed with metastatic meningiomas. The computed tomography (CT) scan revealed the presence of large masses in the right thoracic and abdominal cavity. After two cycles of anti-PD-1 and anti-VEGF treatment, the symptoms were relieved and the tumor was necrotic. Follow up to June 21, 2022, the patient has been given eleven cycles of the treatment every 3 weeks without tumor progression. CONCLUSIONS: This case showed combined anti-PD-1 and anti-VEGF treatment stimulates peripheral blood immune cells to kill metastatic meningioma cells. Whether combined immunotherapy is more effective for metastatic meningioma needs further exploration.
format Online
Article
Text
id pubmed-9588214
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-95882142022-10-24 A rare case report of recurrent atypical meningioma with multiple metastases treated with anti-PD-1 and anti-VEGF therapy Zhao, Jia-Li Liu, Jing Fang, Ming Luo, Chen Gu, Zhen-Bang Huang, Long BMC Neurol Case Report BACKGROUND: Meningioma is the most common type of primary intracranial tumor with 0.1–1% of all primary meningiomas have been reported to develop into metastases. However, there is no proven therapeutic strategy for multiple metastases of meningiomas. CASE PRESENTATION: A 60-year-old female accepted total tumor resection of a right frontal lobe meningioma in September 2018, In October 2021, the patient was admitted to hospital because of cough and shortness of breath and diagnosed with metastatic meningiomas. The computed tomography (CT) scan revealed the presence of large masses in the right thoracic and abdominal cavity. After two cycles of anti-PD-1 and anti-VEGF treatment, the symptoms were relieved and the tumor was necrotic. Follow up to June 21, 2022, the patient has been given eleven cycles of the treatment every 3 weeks without tumor progression. CONCLUSIONS: This case showed combined anti-PD-1 and anti-VEGF treatment stimulates peripheral blood immune cells to kill metastatic meningioma cells. Whether combined immunotherapy is more effective for metastatic meningioma needs further exploration. BioMed Central 2022-10-22 /pmc/articles/PMC9588214/ /pubmed/36273133 http://dx.doi.org/10.1186/s12883-022-02919-4 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Case Report
Zhao, Jia-Li
Liu, Jing
Fang, Ming
Luo, Chen
Gu, Zhen-Bang
Huang, Long
A rare case report of recurrent atypical meningioma with multiple metastases treated with anti-PD-1 and anti-VEGF therapy
title A rare case report of recurrent atypical meningioma with multiple metastases treated with anti-PD-1 and anti-VEGF therapy
title_full A rare case report of recurrent atypical meningioma with multiple metastases treated with anti-PD-1 and anti-VEGF therapy
title_fullStr A rare case report of recurrent atypical meningioma with multiple metastases treated with anti-PD-1 and anti-VEGF therapy
title_full_unstemmed A rare case report of recurrent atypical meningioma with multiple metastases treated with anti-PD-1 and anti-VEGF therapy
title_short A rare case report of recurrent atypical meningioma with multiple metastases treated with anti-PD-1 and anti-VEGF therapy
title_sort rare case report of recurrent atypical meningioma with multiple metastases treated with anti-pd-1 and anti-vegf therapy
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9588214/
https://www.ncbi.nlm.nih.gov/pubmed/36273133
http://dx.doi.org/10.1186/s12883-022-02919-4
work_keys_str_mv AT zhaojiali ararecasereportofrecurrentatypicalmeningiomawithmultiplemetastasestreatedwithantipd1andantivegftherapy
AT liujing ararecasereportofrecurrentatypicalmeningiomawithmultiplemetastasestreatedwithantipd1andantivegftherapy
AT fangming ararecasereportofrecurrentatypicalmeningiomawithmultiplemetastasestreatedwithantipd1andantivegftherapy
AT luochen ararecasereportofrecurrentatypicalmeningiomawithmultiplemetastasestreatedwithantipd1andantivegftherapy
AT guzhenbang ararecasereportofrecurrentatypicalmeningiomawithmultiplemetastasestreatedwithantipd1andantivegftherapy
AT huanglong ararecasereportofrecurrentatypicalmeningiomawithmultiplemetastasestreatedwithantipd1andantivegftherapy
AT zhaojiali rarecasereportofrecurrentatypicalmeningiomawithmultiplemetastasestreatedwithantipd1andantivegftherapy
AT liujing rarecasereportofrecurrentatypicalmeningiomawithmultiplemetastasestreatedwithantipd1andantivegftherapy
AT fangming rarecasereportofrecurrentatypicalmeningiomawithmultiplemetastasestreatedwithantipd1andantivegftherapy
AT luochen rarecasereportofrecurrentatypicalmeningiomawithmultiplemetastasestreatedwithantipd1andantivegftherapy
AT guzhenbang rarecasereportofrecurrentatypicalmeningiomawithmultiplemetastasestreatedwithantipd1andantivegftherapy
AT huanglong rarecasereportofrecurrentatypicalmeningiomawithmultiplemetastasestreatedwithantipd1andantivegftherapy